CLINICAL_TRIALS
trial_result
· 2018-12-19
Clinical Trial Update: Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia [Phase 3]
Summary
A Phase 3 rollover study evaluating continuing valbenazine (NBI-98854) for tardive dyskinesia has completed and posted results in 2018.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Neurocrine Biosciences | Conditions: Tardive Dyskinesia | Phase 3 | Status: COMPLETED | Results posted: 2018-12-19